OOIR: Observatory of International Research

Papers

(The H4-Index of Europace is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Zero-fluoroscopy trans-septal puncture and catheter ablation of a left atrial tachycardia in a pregnant woman with a prosthetic mitral valve	286
How can we assess the risk for sudden cardiac death to decide for primary prophylactic implantable cardioverter-defibrillator in patients with heart failure in 2022?	256
Atrioventricular dromotropathy: an important substrate for complete resynchronization therapy—Authors’ reply	253
Personalized subcutaneous implantable cardioverter-defibrillator sensing vectors generated by mathematical rotation increase device eligibility whilst preserving device performance	252
Administrative data confirm safety of same-day discharge following catheter ablation of atrial fibrillation: all good or is there a fly in the ointment?	185
Impact of sodium-glucose co-transporter inhibitors on cardiac autonomic function and mortality: no time to die	180
Mexiletine for recurrent ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter defibrillator: an EHRA systematic review	165
Reduction in long-term mortality using remote device monitoring in a large real-world population of patients with implantable defibrillators	136
Carbon footprint of atrial fibrillation catheter ablation	115
Extraction of lumenless pacing leads from the His bundle and left bundle branch area: outcomes of the high-volume centre	103
Interpolation of electrophysiology parameters using OpenEP: technology development and clinical application	96
Magnetic resonance imaging in patients with cardiac implantable electronic devices: the RESONANCE Spanish registry	95
Clinical validation of an artificial intelligence algorithm offering automated corrected QT-interval measurements from a single lead electrocardiogram	88
Cardiac magnetic resonance to evaluate 3D ventricular substrate depth: Prognostic implications for VT ablation approach	84
Cardiac magnetic resonance - aided ventricular tachycardia substrate ablation	80
Left atrial low-voltage areas, but not volume, predict the recurrence of atrial fibrillation in repeat ablation procedures	78
Advanced vascular aging in patients with paroxysmal atrial fibrillation - Data from RACE V	78
Artificial intelligence assisted QT interval measurement in 12-lead-ECGs	74
First experience of focal pulsed field ablation for premature ventricular contractions	74
High-density sequential mapping of repetitive atrial conduction patterns during atrial fibrillation	74
The role of local impedance drop in the acute lesion efficacy during pulmonary vein isolation performed with a new contact force sensing catheter	73
Comparison between Novel and Conventional Electrocardiographic Markers of Atrial Cardiomyopathy for identification of Persons at Risk for Ischemic Stroke	70
Different predictors of AF recurrence after pulmonary vein isolation with cryoballoon and radiofrequency ablation: insights from clinical and electroanatomical mapping data of the NO-PERSAF study	69
Aggressive ablation vs. regular ablation for persistent atrial fibrillation: a multicentre real-world cohort study	69
The predictive ability of the QT response in supine-standing test for drug induced QT prolongation	67

Benefit of integrated care in patients with atrial fibrillation- a predictive heterogeneous treatment effect analysis of the ALL-IN trial	64
Pulmonary vein isolation with the novel radiofrequency balloon catheter: predictors of single-shot isolation	62
Pulsed field ablation of persistent and long-standing persistent atrial fibrillation: acute safety, efficacy and long-term outcome from a nationwide experience	59
A Bayesian meta-analysis on recurrence of atrial arrhythmia between Hybrid AF ablation and endocardial AF ablation	58
Stiff but keeping the beat: catheter ablation for atrial fibrillation in cardiac amyloidosis and sarcoidosis	55
Left-sided slow pathway ablation for atrioventricular nodal reentrant tachycardia: a single center experience	55
The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study	52
Different approaches to atrial fibrillation ablation in heart failure patients: temporal trends and clinical outcomes	51
Prevalence and characteristics of arrhythmias during the pregnancy	50
Impaired heart rate variability triangular index predicts stroke and systemic embolism in patients with atrial fibrillation	50
Discussions on implantable cardioverter defibrillator deactivation in patients receiving radiation therapy	50
Hemolysis after atrial fibrillation ablation conducted with a new point-by-point pulsed field ablation device	49
Long-term heart failure improvement after catheter ablation of persistent atrial fibrillation in heart failure with preserved, mildly reduced and reduced ejection fraction	49
Left atrial epicardial adipose tissue: correlation to left atrial fibrosis and arrhythmia recurrence post atrial fibrillation ablation	49
Impact of additional pulsed field ablation in unsuccessful radiofrequency linear lesions -acute and chronic data	48
Identification of a real-world clinical model associated with atrial fibrillation in a large french primary care database	48
Does the rhythm have an additional effect - left atrial strain measurement in heart failure patients with HFrEF and in patients with atrial fibrillation and preserved ejection fraction	47
Ultra-high density mapping and ablation of localized microreentrant tachycardias: insight from the CHARISMA registry	47
Appropriate therapy for implantable cardioverter defibrillators used as primary versus secondary prophylaxis	46
Optical mapping and optogenetics in cardiac electrophysiology research and therapy: a state-of-the-art review	44
The link between ischaemic stroke, ischaemic heart disease, and atrial fibrillation	44